by Ishai Menache, Jeevan Pathuri, David Simchi-Levi and Tom Linton Companies face a variety of complex challenges in designing and optimizing their supply chains. Increasing their resilience ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

At issue is the role pharmacy benefit mangers play in taking large discounts on drugs that advocates say are not passed along ...

A key provision in the new legislation could affect compensation for brokers or consultants who help employers hire pharmacy ...

With multiple stakeholders involved with different interests, the “specialty drug” definition can be a moving target.

It's the latest in a series of lawsuits against Express Scripts and Optum, as pharmacy benefit managers begin to come under more scrutiny.

One would cap insulin at $35 a month, and the other would regulate pharmacy benefit managers. The governor vetoed earlier ...

There’s a lot to criticize about the last-minute process that left the Massachusetts Legislature passing 110 pages of complex ...